ACP-105

guinea pig

Also seen as: ACP105, ACP 105, ACP

The Dose Guy’s verdict

Sep 1, 2026
3 sources

ACP-105 is an obscure research SARM sold on novelty. One rat study, some mouse cognitive work, and a single human urine sample after a microdose, which is a metabolism data point, not a trial. The pitch is “milder than the big SARMs with fewer sides,” but there is no human data to back that up. If you want mild, ostarine has actual trials. ACP-105 is the experiment.

Would I take it?Not with zero human outcome data.

What it is

Acadia Pharmaceuticals built ACP-105 alongside AC-262 as a partial androgen receptor agonist, a SARM that activates the receptor at lower intensity than testosterone. The more interesting sidetrack is the brain work: mouse studies tested ACP-105 for neurological effects, where it reduced anxiety and, combined with the estrogen receptor beta agonist AC-186, improved cognition and reduced brain amyloid in a transgenic Alzheimer’s model. That is why you see it mentioned in nootropic circles. But those are transgenic mice, not people, and the cognition angle has never been tested in a human.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Rat anabolics, mouse brains, and one human urine cup. No therapeutic trial in a person:

ACP-105 improved anabolic parameters during a two-week chronic study in castrated male rats.J Med Chem 2009 · cell + rat

In gonadectomized triple-transgenic Alzheimer’s mice, ACP-105 reduced anxiety-like behavior. Combined with the estrogen receptor beta agonist AC-186, it improved cognition and reduced brain amyloid-beta levels.ACS Chem Neurosci 2013 · transgenic mouse

One human urine sample after a single 100-microgram dose contained seven tentatively identified metabolites. The only human data point that exists for ACP-105.J Chromatogr B 2023 · human metabolism · n=1

No therapeutic human trial reporting ACP-105 efficacy or safety has been published.as of Aug 2026

Realistic protocols

No human dose has been tested for any outcome that matters. Forum dosing runs 5 to 10 mg daily for six to eight weeks, but that range is community lore, not evidence. If you run it: source with a COA first, because a compound this obscure on the grey market could be anything in the capsule. Bloodwork before and after, covering testosterone, lipids, and liver enzymes. Suppression is the class tax, plan your PCT before you start. Every SARM is WADA-prohibited in tested sport.

Side effects

No human adverse-event data from any trial. The SARM class expectation and community noise:

anecdotalTestosterone suppression, expected from the pharmacology. Degree and recovery timeline unknown for ACP-105 specifically.

anecdotalHeadaches reported by some users, unverified against any controlled baseline.

unknownNo human safety profile exists. Not one adverse event has been formally measured.

Where to buy

No live listings from tracked vendors right now.